Briapro Therapeutics
13F holders, Q1 2026 (March 31)2holders +1
1new positions
0sold out
$0.00avg. 13F price*
At the end of Q1 2026, 2 institutions reported holding Briapro Therapeutics in their 13F filings, up 1 from Q4 2025. 1 opened new positions and 0 sold out. The largest holders were Thurston, Springer, Miller, Herd & Titak, Inc. ($0) and Ascentis Independent Advisors ($0).
- Company
- Briapro Therapeutics
- CUSIP
- 107931107
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 40 shares bought, net +40 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Thurston, Springer, Miller, Herd & Titak, Inc. | 0.00% | No change | 123 | $0 |
| Ascentis Independent Advisors | 0.00% | New | 40 | $0 |
"% of holder's portfolio" is BRIAPRO THERAPEUTICS's weight in each manager's 13F, not the share of Briapro Therapeutics the manager owns.